COVID-19 surveillance contributed to sequencing revenue growth and helped Illumina beat analysts' top-line estimates, but it was not the primary growth driver.
For the three months ended March 31, the firm said that preliminary revenues for Q1 are expected to be $1.4 million compared with $3.2 million a year ago.
The company showed that its chip can detect SNPs in models of sickle-cell disease and amyotrophic lateral sclerosis, without the need for DNA amplification.
The genome engineering company has started shipping its Onyx platform commercially, including to the University of Liverpool's synthetic biology foundry GeneMill.
The DRP would be used to identify kidney cancer patients likely to benefit from dovitinib, a repurposed TKI for which Allarity plans to file an NDA this year.
The assay is Guardant Health’s first commercially available product for clinical management of early-stage tumors and is initially focused on colorectal cancer.
The firm's assay leverages reverse transcriptase quantitative PCR to amplify two separate regions of the HIV-1 genome to monitor HIV-infected patients.
The company said that it is on track to meet its goal of shaving $7.2 million in costs this year as it undertakes a recently announced restructuring plan.
The companies will integrate their respective technologies into a platform for clinical genetics services, including test ordering and virtual counseling.
The company is planning to commercialize its cancer early detection technology initially in lung cancer and is working with NYU researchers to explore future expansions.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
